Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an open-label, multicenter, phase 1b study, which is designed to explore the safety, efficacy and PK of olverembatinib, a third-generation tyrosine kinase inhibitor (TKI) marketed in China, in combination with APG-2575 in treating R/R Ph+ALL children, and to preliminarily establish the recommended dose of olverembatinib and APG-2575 for children based on the above results.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dziecko poniżej 18 lat, zdolne do przyjmowania leków w postaci tabletek do połknięcia
- •Rozpoznana białaczka limfoblastyczna Philadelphia-dodatnia, która powróciła lub nie reaguje na co najmniej jeden lek z grupy inhibitorów tyrozyny kinazy
- •Zgoda rodzica lub opiekuna prawnego na udział w badaniu
- •Ogólny stan zdrowia dziecka pozwalający na udział w badaniu (wynik 50 lub wyższy w skali oceny stanu)
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Dla dziewczynek w wieku rozrodczym: ujemny test ciąży
- •Prawidłowe wyniki badań nerek, wątroby, trzustki i krwi w zakresie normy
Simplified criteria — AI translation
Trial details
- Minimum age
- 1 Year
- Maximum age
- 18 Years
- Last updated (source)
- August 26, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
The Second Affiliated Hospital of Anhui Medical University
Hefei, China
Qilu Hospital of Shandong University
Jinan, China
Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences
Tianjin, China
Department of Hematology/Oncology, Shanghai Jiaotong University School of Medicine Affiliated Shanghai Children's Medical Center
Shanghai, China
Trial contact
Jingliao Zhang, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/27/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.